Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small cell lung cancer with brain metastases

TW202641542APending Publication Date: 2026-10-16TYK MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115124495
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-11
Filing Date
2025-05-09
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001081413_001
    Figure TWG2TA001081413_001
  • Figure TWG2TA001081413_002
    Figure TWG2TA001081413_002
  • Figure TWG2TA001081413_003
    Figure TWG2TA001081413_003
Patent Text Reader

Abstract

This invention discloses a method for treating brain metastases of EGFR mutation-positive non-small cell lung cancer by administering an effective dose of an EGFR inhibitor, wherein the EGFR inhibitor is N-(2-((2-(dimethylamine)ethyl)(methyl)amine)-4-methoxy-5-((4-(1-deuterated methyl-1H-indol-3-yl)pyrimidin-N'-2-yl)amine)phenyl)acrylamide methanesulfonate.
Need to check novelty before this filing date? Find Prior Art